Breast Cancer Screening Recommendations for Transgender Women on Estradiol

Screening Initiation Criteria

• Begin mammography screening at age 40 after ≥ 5 years of continuous estradiol therapy, or at age 50 regardless of hormone duration for a more conservative approach【1】.
• The pivotal threshold for initiating screening is ≥ 5 years of feminizing hormone therapy【2】.

Average‑Risk Screening Strategies

• Fenway Health recommends annual screening mammography starting at age 50 for transgender women with ≥5 years of estradiol exposure【3】.
• UCSF Center of Excellence recommends biennial screening mammography starting at age 50 for the same population【3】.
• For individuals with < 5 years of estradiol therapy, routine screening is not required according to Fenway Health and UCSF guidelines【4】.

High‑Risk Considerations

• For transgender women with ≥5 years of hormone use plus high‑risk factors (e.g., personal breast cancer history, prior chest irradiation, pathogenic BRCA1/2 or other breast‑cancer predisposition genes, first‑degree relative with a genetic predisposition), the American College of Radiology (ACR) deems digital breast tomosynthesis or mammography “usually appropriate”【1】.

Incidence and Relative Risk

Data derived from cohort studies of transgender women receiving estrogen【2】.

• Breast‑cancer risk rises within a relatively short hormone exposure period (median 18 years, range 7‑37 years in Dutch cohorts)【2】.

Imaging Modality Selection

• Both digital breast tomosynthesis (3‑D mammography) and standard digital mammography are acceptable screening modalities for transgender women on estradiol【2】.

Pathology Expectations

• The spectrum of breast pathology in transgender women mirrors that of cisgender women, including ductal and lobular carcinomas, fibroadenomas, cysts, and malignant phyllodes tumors【5】.

Practical Implementation Algorithm

• Age < 40 with < 5 years of estradiol → No routine screening【4】.
• Annual screening (Fenway Health)【3】.
• Biennial screening (UCSF, aligns with cisgender‑women guidelines)【3】.

Guideline Consensus and Evidence Gaps

• There is notable discordance among guidelines: the most conservative approach (screen at 50 years after ≥ 5 years of hormone therapy) minimizes false positives but may miss early cancers, whereas the aggressive approach (screen at 40 years following cisgender‑women recommendations) maximizes early detection but raises false‑positive and overdiagnosis risks【1】【4】【2】.
• The evidence base is limited; recommendations extrapolate from cisgender data and small transgender cohorts with heterogeneous hormone regimens and short follow‑up periods【2】【5】【3】.

Additional Clinical Considerations

• Breast density increases with estrogen therapy, potentially reducing mammographic sensitivity; digital breast tomosynthesis may mitigate this limitation【1】 (note: evidence statement excluded due to ignore‑ref flag).
• Surgical history such as breast augmentation should be documented, as implants can affect imaging interpretation and may require supplemental views【5】.

Breast Cancer Screening for Transgender Women on Estrogen Therapy

Risk Assessment and Screening Rationale

• The American College of Radiology recommends that digital breast tomosynthesis or mammography screening "may be appropriate" for average-risk transgender women who are 40 years or older with past or current hormone use for 5 years 6, 7
• Breast cancer risk increases in transgender women on feminizing hormone therapy compared to cisgender men, but remains lower than cisgender women 8, 9
• A 45-year-old transgender female on estrogen therapy for 4 years is approaching the 5-year threshold that guidelines use for risk stratification, making breast cancer screening an appropriate preventive measure 10, 8

Screening Recommendations Based on Guidelines

• The Endocrine Society recommends transgender women undergo breast cancer screening similar to cisgender women, typically starting at age 40 11, 12
• Fenway Health recommends annual screening mammography starting at age 50 for those with ≥5 years of hormone therapy 11, 12
• The UCSF Center of Excellence recommends biennial screening mammography starting at age 50 for those with ≥5 years of hormone therapy 11, 12
• The American College of Radiology recommends digital breast tomosynthesis or mammography screening for those 40 years or older with ≥5 years of hormone use 6, 7

Clinical Pearls and Caveats

• Exogenous estrogen therapy is associated with increased breast cancer risk in both cisgender and transgender populations 8
• Breast tissue in transgender women on hormone therapy develops ducts, lobules, and acini histologically identical to cisgender females 9
• Digital breast tomosynthesis (3D mammography) may provide better visualization in patients with dense breast tissue, which can develop in transgender women on estrogen therapy 7, 13

Monitoring and Follow-up

• Once the patient reaches the 5-year threshold of hormone therapy, regular breast cancer screening should be maintained according to guidelines 10, 11
• Consider reassessing breast cancer risk periodically, especially if family history changes or if hormone regimens are modified 10, 8

Mammography Screening Guidelines for Transgender Women on Hormone Therapy

Average‑Risk Recommendations

Society‑Specific Recommendations

Risk‑Stratified Approach